Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Peripheral blood mononuclear cells derived from grand multigravidae display a distinct cytokine profile in response to P. falciparum infected erythrocytes.

Ludlow LE, Hasang W, Umbers AJ, Forbes EK, Ome M, Unger HW, Mueller I, Siba PM, Jaworowski A, Rogerson SJ.

PLoS One. 2014 Jan 22;9(1):e86160. doi: 10.1371/journal.pone.0086160. eCollection 2014.

2.

Assessment of antibody-dependent respiratory burst activity from mouse neutrophils on Plasmodium yoelii malaria challenge outcome.

Llewellyn D, de Cassan SC, Williams AR, Douglas AD, Forbes EK, Adame-Gallegos JR, Shi J, Pleass RJ, Draper SJ.

J Leukoc Biol. 2014 Feb;95(2):369-82. doi: 10.1189/jlb.0513274. Epub 2013 Oct 25.

3.

The utility of Plasmodium berghei as a rodent model for anti-merozoite malaria vaccine assessment.

Goodman AL, Forbes EK, Williams AR, Douglas AD, de Cassan SC, Bauza K, Biswas S, Dicks MD, Llewellyn D, Moore AC, Janse CJ, Franke-Fayard BM, Gilbert SC, Hill AV, Pleass RJ, Draper SJ.

Sci Rep. 2013;3:1706. doi: 10.1038/srep01706.

4.

T cell responses induced by adenoviral vectored vaccines can be adjuvanted by fusion of antigen to the oligomerization domain of C4b-binding protein.

Forbes EK, de Cassan SC, Llewellyn D, Biswas S, Goodman AL, Cottingham MG, Long CA, Pleass RJ, Hill AV, Hill F, Draper SJ.

PLoS One. 2012;7(9):e44943. doi: 10.1371/journal.pone.0044943. Epub 2012 Sep 12.

5.

Recombinant viral-vectored vaccines expressing Plasmodium chabaudi AS apical membrane antigen 1: mechanisms of vaccine-induced blood-stage protection.

Biswas S, Spencer AJ, Forbes EK, Gilbert SC, Holder AA, Hill AV, Draper SJ.

J Immunol. 2012 May 15;188(10):5041-53. doi: 10.4049/jimmunol.1101106. Epub 2012 Apr 13.

6.

Combining liver- and blood-stage malaria viral-vectored vaccines: investigating mechanisms of CD8+ T cell interference.

Forbes EK, Biswas S, Collins KA, Gilbert SC, Hill AV, Draper SJ.

J Immunol. 2011 Oct 1;187(7):3738-50. doi: 10.4049/jimmunol.1003783. Epub 2011 Aug 29.

7.

The requirement for potent adjuvants to enhance the immunogenicity and protective efficacy of protein vaccines can be overcome by prior immunization with a recombinant adenovirus.

de Cassan SC, Forbes EK, Douglas AD, Milicic A, Singh B, Gupta P, Chauhan VS, Chitnis CE, Gilbert SC, Hill AV, Draper SJ.

J Immunol. 2011 Sep 1;187(5):2602-16. doi: 10.4049/jimmunol.1101004. Epub 2011 Aug 3.

8.

The generation and evaluation of recombinant human IgA specific for Plasmodium falciparum merozoite surface protein 1-19 (PfMSP1 19).

Shi J, McIntosh RS, Adame-Gallegos J, Dehal PK, van Egmond M, van de Winkel J, Draper SJ, Forbes EK, Corran PH, Holder AA, Woof JM, Pleass RJ.

BMC Biotechnol. 2011 Jul 22;11:77. doi: 10.1186/1472-6750-11-77.

9.

CD8+ T effector memory cells protect against liver-stage malaria.

Reyes-Sandoval A, Wyllie DH, Bauza K, Milicic A, Forbes EK, Rollier CS, Hill AV.

J Immunol. 2011 Aug 1;187(3):1347-57. doi: 10.4049/jimmunol.1100302. Epub 2011 Jun 29.

10.

Recombinant Viral Vaccines Expressing Merozoite Surface Protein-1 Induce Antibody- and T Cell-Mediated Multistage Protection against Malaria.

Draper SJ, Goodman AL, Biswas S, Forbes EK, Moore AC, Gilbert SC, Hill AVS.

Cell Host Microbe. 2011 Mar 17;9(3):252. doi: 10.1016/j.chom.2011.03.002. Epub 2011 Mar 16. No abstract available.

11.

Toward the discovery of vaccine adjuvants: coupling in silico screening and in vitro analysis of antagonist binding to human and mouse CCR4 receptors.

Davies MN, Bayry J, Tchilian EZ, Vani J, Shaila MS, Forbes EK, Draper SJ, Beverley PC, Tough DF, Flower DR.

PLoS One. 2009 Nov 30;4(11):e8084. doi: 10.1371/journal.pone.0008084.

12.

Recombinant viral vaccines expressing merozoite surface protein-1 induce antibody- and T cell-mediated multistage protection against malaria.

Draper SJ, Goodman AL, Biswas S, Forbes EK, Moore AC, Gilbert SC, Hill AV.

Cell Host Microbe. 2009 Jan 22;5(1):95-105. doi: 10.1016/j.chom.2008.12.004.

13.

Immunogenicity and protective efficacy of prime-boost regimens with recombinant (delta)ureC hly+ Mycobacterium bovis BCG and modified vaccinia virus ankara expressing M. tuberculosis antigen 85A against murine tuberculosis.

Tchilian EZ, Desel C, Forbes EK, Bandermann S, Sander CR, Hill AV, McShane H, Kaufmann SH.

Infect Immun. 2009 Feb;77(2):622-31. doi: 10.1128/IAI.00685-08. Epub 2008 Dec 8. Erratum in: Infect Immun. 2011 May;79(5):2133.

14.
15.

In silico identified CCR4 antagonists target regulatory T cells and exert adjuvant activity in vaccination.

Bayry J, Tchilian EZ, Davies MN, Forbes EK, Draper SJ, Kaveri SV, Hill AV, Kazatchkine MD, Beverley PC, Flower DR, Tough DF.

Proc Natl Acad Sci U S A. 2008 Jul 22;105(29):10221-6. doi: 10.1073/pnas.0803453105. Epub 2008 Jul 11.

16.

South Thames Nuclear Medicine Survey 1996-97. South Thames Regional Nuclear Medicine Specialty Service Committee.

Wells CP, Burwood RJ, Forbes EK.

Nucl Med Commun. 1997 Nov;18(11):1098-108.

PMID:
9423211

Supplemental Content

Loading ...
Support Center